Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
Contraception and HRT prescribing in patients on GLP-1 agonist weight-loss drugs GP with an interest in womens health Dr Toni Hazell discusses the recent rise in the use of injectable GLP-1 receptor agonists for weight loss and the challenges this can pose when prescribing contraception or HRT GLP-1 agonists arent widely available on the NHS, so why is this a big issue
Animal studies showed that exposure to GLP1-RAs was associated with small-for-gestational age pups (birthweight that is lower than expected at the time of delivery), and there was an increased risk of birth defects compared to unexposed animals
They also support the nervous system and help regulate mood, which can be beneficial for managing stress and anxiety associated with adrenal fatigue
